For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
In the latest session, Charles River Laboratories International Inc (NYSE: CRL) closed at $161.35 down -3.37% from its previous closing price of $166.98. In other words, the price has decreased by -$3.37 from its previous closing price. On the day, 0.93 million shares were traded. CRL stock price reached its highest trading level at $168.0 during the session, while it also had its lowest trading level at $161.11.
Ratios:
For a deeper understanding of Charles River Laboratories International Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 40.42 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.45. For the most recent quarter (mrq), Quick Ratio is recorded 1.13 and its Current Ratio is at 1.41. In the meantime, Its Debt-to-Equity ratio is 0.80 whereas as Long-Term Debt/Eq ratio is at 0.79.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on March 21, 2025, Downgraded its rating to Neutral and sets its target price to $170 from $190 previously.
On March 04, 2025, Citigroup Upgraded its rating to Neutral which previously was Sell and also upped its target price recommendation from $155 to $175.
Redburn Atlantic Upgraded its Sell to Neutral on March 03, 2025, while the target price for the stock was maintained at $188.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 20 ’25 when FOSTER JAMES C bought 6,075 shares for $165.01 per share. The transaction valued at 1,002,436 led to the insider holds 183,639 shares of the business.
Girshick Birgit bought 1,514 shares of CRL for $249,250 on Feb 20 ’25. The Corporate Executive VP & COO now owns 55,058 shares after completing the transaction at $164.63 per share. On Feb 20 ’25, another insider, LaPlume Joseph W, who serves as the EVP, Corp Strategy & Develop of the company, sold 4,400 shares for $162.50 each. As a result, the insider received 715,000 and left with 20,013 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRL now has a Market Capitalization of 8539626496 and an Enterprise Value of 10884749312. As of this moment, Charles’s Price-to-Earnings (P/E) ratio for their current fiscal year is 629.04, and their Forward P/E ratio for the next fiscal year is 15.71. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 183.40. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.04 while its Price-to-Book (P/B) ratio in mrq is 2.38. Its current Enterprise Value per Revenue stands at 2.688 whereas that against EBITDA is 12.118.
Stock Price History:
The Beta on a monthly basis for CRL is 1.43, which has changed by -0.40100974 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, CRL has reached a high of $273.57, while it has fallen to a 52-week low of $150.79. The 50-Day Moving Average of the stock is -2.98%, while the 200-Day Moving Average is calculated to be -16.05%.
Shares Statistics:
For the past three months, CRL has traded an average of 1.14M shares per day and 1102290 over the past ten days. A total of 51.14M shares are outstanding, with a floating share count of 50.57M. Insiders hold about 1.12% of the company’s shares, while institutions hold 105.01% stake in the company. Shares short for CRL as of 1741910400 were 3301195 with a Short Ratio of 2.56, compared to 1739491200 on 2319466. Therefore, it implies a Short% of Shares Outstanding of 3301195 and a Short% of Float of 8.37.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
As of right now, 14.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $2.37, with high estimates of $2.57 and low estimates of $2.26.
Analysts are recommending an EPS of between $9.49 and $9.13 for the fiscal current year, implying an average EPS of $9.35. EPS for the following year is $10.27, with 17.0 analysts recommending between $10.8 and $9.76.
Revenue Estimates
A total of 11 analysts believe the company’s revenue will be $941.37M this quarter.It ranges from a high estimate of $954.84M to a low estimate of $928.43M. As of the current estimate, Charles River Laboratories International Inc’s year-ago sales were $1.01BFor the next quarter, 11 analysts are estimating revenue of $958.79M. There is a high estimate of $968.33M for the next quarter, whereas the lowest estimate is $952M.
A total of 15 analysts have provided revenue estimates for CRL’s current fiscal year. The highest revenue estimate was $3.87B, while the lowest revenue estimate was $3.77B, resulting in an average revenue estimate of $3.82B. In the same quarter a year ago, actual revenue was $4.05BBased on 16 analysts’ estimates, the company’s revenue will be $4.03B in the next fiscal year. The high estimate is $4.38B and the low estimate is $3.95B.
